Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Grifols S.A. (GRFS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,524,188
  • Shares Outstanding, K 687,554
  • Annual Sales, $ 5,299 M
  • Annual Income, $ 704,630 K
  • 60-Month Beta 1.04
  • Price/Sales 2.56
  • Price/Cash Flow 12.62
  • Price/Book 2.43

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate 0.31
  • Number of Estimates 3
  • High Estimate 0.34
  • Low Estimate 0.29
  • Prior Year 0.34
  • Growth Rate Est. (year over year) -8.82%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.57 +14.97%
on 05/31/19
20.22 -0.10%
on 06/20/19
+2.12 (+11.73%)
since 05/20/19
3-Month
17.57 +14.97%
on 05/31/19
20.41 -1.00%
on 04/02/19
+1.08 (+5.65%)
since 03/20/19
52-Week
17.42 +15.96%
on 12/24/18
22.90 -11.79%
on 06/22/18
-2.70 (-11.79%)
since 06/20/18

Most Recent Stories

More News
Grifols to launch plasma-protein-based bleeding-control solutions

Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced that the VISTASEAL(TM) fibrin sealant...

GRFS : 20.14 (+2.39%)
GRF : 7.82 (+0.17%)
Grifols to launch plasma-protein-based bleeding-control solutions

Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced that the VISTASEAL(TM) fibrin sealant...

GRFS : 20.14 (+2.39%)
GRF : 7.82 (+0.17%)
Grifols to launch plasma-protein-based bleeding-control solutions

Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced that the VISTASEAL(TM) fibrin sealant...

GRFS : 20.14 (+2.39%)
GRF : 7.82 (+0.17%)
Grifols to launch plasma-protein-based bleeding-control solutions

Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced that the VISTASEAL(TM) fibrin sealant...

GRFS : 20.14 (+2.39%)
GRF : 7.82 (+0.17%)
Grifols to launch plasma-protein-based bleeding-control solutions

Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced that the VISTASEAL(TM) fibrin sealant...

GRFS : 20.14 (+2.39%)
GRF : 7.82 (+0.17%)
Grifols to launch plasma-protein-based bleeding-control solutions

Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced that the VISTASEAL(TM) fibrin sealant...

GRFS : 20.14 (+2.39%)
GRF : 7.82 (+0.17%)
Grifols to launch plasma-protein-based bleeding-control solutions

Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced that the VISTASEAL(TM) fibrin sealant...

GRFS : 20.14 (+2.39%)
GRF : 7.82 (+0.17%)
Grifols to launch plasma-protein-based bleeding-control solutions

Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced that the VISTASEAL(TM) fibrin sealant...

GRFS : 20.14 (+2.39%)
GRF : 7.82 (+0.17%)
Grifols to launch plasma-protein-based bleeding-control solutions

Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced that the VISTASEAL(TM) fibrin sealant...

GRFS : 20.14 (+2.39%)
GRF : 7.82 (+0.17%)
Grifols to launch plasma-protein-based bleeding-control solutions

Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced that the VISTASEAL(TM) fibrin sealant...

GRFS : 20.14 (+2.39%)
GRF : 7.82 (+0.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade GRFS with:

Business Summary

Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience...

See More

Key Turning Points

2nd Resistance Point 19.85
1st Resistance Point 19.76
Last Price 20.14
1st Support Level 19.55
2nd Support Level 19.43

See More

52-Week High 22.90
Fibonacci 61.8% 20.81
Fibonacci 50% 20.16
Last Price 20.14
Fibonacci 38.2% 19.51
52-Week Low 17.42

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar